成員介紹 » 副校長

陳志鴻 副校長

副校長 陳志鴻 教授

副校長 陳志鴻 教授

聯絡資訊

 

現職

  • 中國醫藥大學 副校長
  • 中國醫藥大學醫學系教授、醫學院院長
  • 中國醫藥大學附設醫院內科學科主治醫師、顧問

 

學歷

年度 學歷
1983-1987 國立台灣大學醫學院臨床醫學研究所,博士
1970-1977 國立台灣大學醫學院醫學系,醫學士

 

經歷

年度 經歷
2003-2009 國立成功大學醫學院附設醫院院長
1990-1998 國立成功大學附設醫院教學副院長
1989-1996 國立成功大學附設醫院內科部主任
1997/6-1998/7 國立成功大學醫學院教務分處主任
1993/4-1993/6 The Johns Hopkins University Medical School, Visiting Professor
1996/2-1996/6 The William Harvey Research Institute, Visiting Professor, London
2010-2012 中華民國心臟學會理事長
2013-2015 亞太心臟學會副會長

 

獎譽

年度 經歷
1989 國立成功大學和教育部優良教師獎
1990 獲得教育部長〝優良教師〞獎
1990 行政院國家科學發展委員會〝優等研究獎〞
1991 成大醫學院年度優秀論文獎
1991 中華民國心臟學會優秀論文獎
1993 美國心臟學會士(Fellow of the American College of Cardiology)
  國立成功大學優良教師勵人獎
1999 行政院國家科學發展委員會〝甲種研究獎〞
2000 行政院國家科學發展委員會〝甲種研究獎〞
2007 行政院國家科學發展委員會〝研究主持獎〞
2007 國家品質獎
2008 第六屆台灣企業獎〝傑出管理人獎〞

 

專長項目

  • 高血壓
  • 冠心病
  • 血管硬化
  • 心房顫動之抗栓治療

 

著作目錄

SELECTED PUBLICATIONS
TSAI WC, LI YH, LIN CC, CHAO TH and CHEN JH* (2004) Effects of oxidative stress on endothelial function after a high-fat meal. Clinical Science;106: 315-319.
LIU PY, LI YH, TSAI WC,TSAI LM, CHAO TH, WU HL and CHEN JH* (2005) Stromelysin-1 promoter 5A/6A polymorphism is an independent genetic prognostic risk factor and interacts with smoking cessation after index premature myocardial infarction. Journal of Thrombosis and Haemostasis:JTH;3: 1998-2005.
LIU PY, LI YH, WU HL, CHAO TH, TSAI LM, LIN LJ, SHI GY and CHEN JH* (2006) Platelet-activating factor-acetyl hydrolase A379V (exon 11) gene polymorphism is an independent and functional risk factor for premature myocardial infarction. Journal of thrombosis and   haemostasis : JTH ;4: 1023-1028.
LIU PY, LI YH, CHANG SH, LIN LJ, WU HL, SHI GY and CHEN JH* (2006) Genotype-phenotype association of matrix metalloproteinase-3 polymorphism and its synergistic effect with smoking on the occurrence of acute coronary syndrome. The American journal of cardiology ;98: 1012-1017.
TSAI WC, LI YH, HUANG YY, LIN CC, CHAO TH and CHEN JH* (2006) Plasma vascular endothelial growth factor as a marker for early vascular damage in hypertension. Clinical Science; 109: 39-43.
LIU PY, LI LH, CHAO TH, WU HL, LIN LJ, TSAI LM and CHEN JH* (2007) Synergistic effect of cytochrome P450 epoxygenase CYP2J2*7 polymorphism with smoking on the onset of premature myocardial infarction. Atherosclerosis. 195: 199-206.
LIU PY, CHEN JH, LIN LJ and James K. LIAO, (2007). Incerased Rho kinase (ROCK) activity in a taiwanese population with metabolic syndrome. J Am Coll Cardiol. 49(15) 1619-1624.
The ONTARGET Investigators (JH Chen is one of the members of steering committee), (2008). Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. N Engl J Med 2008;358:1547-59.
The TRANSCEND Investigators (JH Chen is one of the members of steering committee), (2008). Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet 2008:372:1174-83.
LIU PY, LIU YW, LIN LJ, CHEN JH, LIAO JK*,(2008). Evidence for Statin Pleiotropy in Humans: Differential Effects of Statins and Ezetimibe on ROCK Activity, Endothelial Function, and Inflammation. Circulation. 2009 Jan 6;119(1):131-8.
Sruart J Connolly, Michael D. Ezekowitz, Salim Yusuf, D.Phil., john Eikelboom, Jonas Oldgren, Amit Parekh, Janice Pogue, Paul A. Reilly, Ellison Themeles, Jeanne Varrone, Susan Wang, Marco Alings, Denis Xavier, Jun Zhu, Rafael Diaz, Basil S. Lewis, Harald Darius, Hans-Christoph Diener, Campbell D. Joyner, Lars Wallentin, and the RE-LY Steering Committee and Investigators, (JH Chen is one of the members of steering committee) (2009). Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.